Abstract
Fundamental and clinical examinations on PC-904, a new semi-synthesized penicillin, were carried out and the following results were obtained.
1) Antibacterial activity of PC-904
The antibacterial activity of PC-904 against the various strains isolated from clinical specimens (10 strains of Staph. aureus, 23 strains of E. coli, 6 strains of Klebsiella, 6 strains of Proteus mirabilis, 11 strains of Pseud. aeruginosa) was in general similar or a few tubes superior to that of ABPC and CBPC.,
2) Absorption and excretion of PC-904
The peak serum levels of PC-904 in 2 healthy volunteers after 1 hour drip infusion of 1g showed 42μg/ml on the average at the end of infusion, and in the case of 30minutes drip infusion of 0.5g in 1 healthy volunteer, the peak level was achieved at the end of infusion and showed 27μg/ml.
Urinary excretion rates were about 35% in these cases.
Biliary excretion of PC-904 after 1g drip infusion was examined in 2 patients. The peak levels were 735 and 315 μg/ml at 2-3 hours after administration and at 5-6 hours 320 and 220 μg/ml were detected respectively. These levels seemed to be so high that PC-904 was expected to be clinically effective against infectious diseases in bile duct.
3) Results of clinical application
PC-904 was administered to 6 infectious cases, and the effects of the drug were considered to be good in 3, fair in 2 and poor in 1.
Among them, no side effects and abnormalities of laboratory findings were noted.
